Retatrutide, Tirzepatide &
Semaglutide: The Evidence
Three generations of GLP-1 based metabolic peptides — each setting a new clinical record. The latest triple receptor co-agonist has produced results never before documented in peer-reviewed obesity pharmacology research.
“Retatrutide produced 24.2% total body weight reduction — the highest result ever documented for a once-weekly metabolic compound.”
Jastreboff AM et al. New England Journal of Medicine, 2023;389:514–526. Phase 2 randomized, double-blind, placebo-controlled trial. 48-week follow-up, highest dose cohort.
Total body weight reduction — Retatrutide Phase 2 Trial, NEJM 2023
Previous record: 20.9% (Tirzepatide SURMOUNT-1, 2022)
The Incretin Evolution: Each Generation Set a New Record
Maximum documented percent total body weight loss from pivotal clinical trials, highest dose cohort
How Fat Loss Peptides Work
Four independent mechanisms working simultaneously to drive metabolic transformation at the cellular level
GLP-1 Compound Comparison
Quick-reference overview of receptor targeting, dosing protocol, and peak efficacy data for each generation










